首頁 > 市場調查報告書 > 製藥

肥胖症

市場調查報告書

商品編碼

1789551

抗肥胖藥物市場（依藥物類別、藥物類型和地區分類）

Anti-Obesity Drug Market, By Mechanism of Action, By Prescription/Non- prescription, And by Region

出版日期: 2025年07月04日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年抗肥胖藥物市場價值估計為 258.7 億美元，預計到 2032 年將達到 825.5 億美元，2025 年至 2032 年的複合年成長率為 18.01%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	258.7億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	18.01%	2032年價值預測	825.5億美元

肥胖通常定義為體重過重。成人肥胖的通常標準是體重指數 (BMI) 達到或超過 30。抗肥胖藥物是一種透過降低體內膽固醇水平來減輕體重的藥物。這些藥物透過調節食慾和卡路里攝取量來影響人體的基本功能。抗肥胖藥物通常用於治療肥胖症。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 已核准多種用於治療肥胖症的抗肥胖藥物。

市場動態

肥胖人口和相關慢性疾病的增加、對超重和肥胖的日益擔憂、對抗肥胖藥物的需求增加、研發的增加以及 COVID-19 疫情的爆發，預計將在預測期內推動全球抗肥胖藥物市場成長的主要因素。例如，2021 年 6 月，美國FDA 批准 2.4 毫克司美格魯肽用於患有肥胖和/或至少一種體重相關疾病（例如高血壓、膽固醇或 2 型Semaglutide）的超重成年人的慢性體重管理，以配合低熱量飲食和核准體力活動。

此外，2021年1月，全球醫療保健公司諾華宣布了一項名為bimagrumab的在臨床實驗藥物的II期臨床試驗結果，該藥物顯示出治療肥胖症的潛力。該藥物目前正在諾華的研發管線中進行研究。

本次調查的主要特點

本報告對全球抗肥胖藥物市場進行了詳細分析，並以 2024 年為基準年，展示了 2025 年至 2032 年預測期內的市場規模和年複合成長率（CAGR%）。
它揭示了各個領域的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、主要亮點、業績和策略等參數，對全球抗肥胖藥物市場的主要企業進行了概述。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球抗肥胖藥物市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過用於分析全球抗肥胖藥物市場的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 25.87 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	18.01%	2032 Value Projection:	USD 82.55 Bn

Obesity is commonly defined as having too much body mass. A body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several anti-obesity drugs to treat obesity.

Market Dynamics

Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive the growth of the global anti-obesity drug market during the forecast period. For instance, in June 2021, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.

Moreover, in January 2021, Novartis, a global healthcare company, announced the results of its Phase II trial of an investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.

Key features of the study

This report provides in-depth analysis of the global Anti-Obesity Drug Market, and provides market size (USD Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Anti-Obesity Drug Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Anti-Obesity Drug Market

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription Drugs
- Over-the-Counter (OTC) Drugs
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- GLP-1 Receptor Agonists
- Semaglutide
- Liraglutide
- Tirzepatide
- MC4R (Melanocortin-4 Receptor) Agonists
- Setmelanotide
- Lipase Inhibitors
- Orlistat
- Noradrenergic & Serotonergic Drugs
- Phentermine
- Diethylpropion
- Phendimetrazine
- Combination Therapies
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Others
- Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
- Empagliflozin
- Canagliflozin
- Bile Acid Sequestrants
- Colesevelam
- Amylin Analogs
- Pramlintide
- Others (Late Phase Drugs, etc.)
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Others (Transdermal)
Type Insights (Revenue, USD Bn, 2020 - 2032)
- Brand
- Generic
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
- Pediatric
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novo Nordisk
- GlaxoSmithKline
- AstraZeneca
- Pfizer
- Merck & Co.
- Sanofi
- Amgen
- Eli Lilly and Company
- Johnson & Johnson
- Takeda Pharmaceutical Company
- Abbott Laboratories
- Orexigen Therapeutics
- Zafgen
- Rhythm Pharmaceuticals
- Currax Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Anti-Obesity Drug Market, By Drug Type
- Global Anti-Obesity Drug Market, By Drug Class
- Global Anti-Obesity Drug Market, By Route of Administration
- Global Anti-Obesity Drug Market, By Type
- Global Anti-Obesity Drug Market, By Gender
- Global Anti-Obesity Drug Market, By Age Group
- Global Anti-Obesity Drug Market, By Distribution Channel
- Global Anti-Obesity Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Anti-Obesity Drug Market, By Drug Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Prescription Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Over-the-Counter (OTC) Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Anti-Obesity Drug Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
GLP-1 Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Semaglutide
    - Liraglutide
    - Tirzepatide
MC4R (Melanocortin-4 Receptor) Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Setmelanotide
Lipase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Orlistat
Noradrenergic & Serotonergic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Phentermine
    - Diethylpropion
    - Phendimetrazine
Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Phentermine/Topiramate
    - Naltrexone/Bupropion
    - Others
Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Empagliflozin
    - Canagliflozin
Bile Acid Sequestrants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

o Colesevelam

Amylin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Pramlintide
Others (Late Phase Drugs, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Anti-Obesity Drug Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Transdermal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Anti-Obesity Drug Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Anti-Obesity Drug Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Anti-Obesity Drug Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Anti-Obesity Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Anti-Obesity Drug Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

12. Competitive Landscape

Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Orexigen Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zafgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Rhythm Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Currax Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies